Baxter selects northern Illinois site for Baxalta global headquarters
Baxalta, the biopharmaceutical company expected to separate from Baxter International in mid-year, will be headquartered in northern Illinois. A long-term lease agreement for an approximately 260,000-square-foot facility extends for more than a decade.
Upon completion of the separation, Baxalta will have approximately $6 billion in global revenues and will be a provider of therapeutic treatments that save, sustain and improve the lives of people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manufacturing experience, Baxalta's broad pipeline is built on a legacy of innovation in bleeding disorders and immunology and is expanding to address unmet medical needs in niche areas of oncology, as well as technology platforms such as gene therapy.